Advertisement

Drugs

, Volume 73, Issue 13, pp 1491–1502 | Cite as

Pertuzumab: A Review of Its Use for First-Line Combination Treatment of HER2-Positive Metastatic Breast Cancer

  • Paul L. McCormack
Adis Drug Evaluation

Abstract

Pertuzumab (Perjeta®) is a humanized anti-HER2 monoclonal antibody that binds to the extracellular dimerization subdomain of the HER2 receptor and reduces HER2 intracellular signalling by preventing HER2 from forming heterodimers with other HER receptors. Inhibition of HER2 signalling results in a reduction of tumour cell proliferation, invasiveness and survival. Pertuzumab and trastuzumab bind to different sites on the HER2 receptor and have complementary antitumour activities; they act synergistically in inhibiting the growth of HER2-overexpressing breast cancer cell lines in vitro. The efficacy of intravenous pertuzumab (840 mg loading dose, then 420 mg every 3 weeks) in combination with trastuzumab plus docetaxel in the first-line treatment of HER2-positive metastatic breast cancer was demonstrated in the randomized, double-blind, placebo-controlled, multinational, phase III CLEOPATRA trial. Pertuzumab in combination with trastuzumab and docetaxel significantly increased independently assessed median progression-free survival (primary endpoint), objective response rate and overall survival compared with placebo in combination with trastuzumab and docetaxel. Pertuzumab had an acceptable tolerability profile when added to trastuzumab and docetaxel in the pivotal CLEOPATRA trial. Thus, pertuzumab is a valuable addition to the growing list of anti-HER2 targeted therapies for breast cancer.

Keywords

Docetaxel Trastuzumab Human Epidermal Growth Factor Receptor Febrile Neutropenia Pertuzumab 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

References

  1. 1.
    Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14(4):320–68.PubMedCrossRefGoogle Scholar
  2. 2.
    Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18–43.PubMedGoogle Scholar
  3. 3.
    Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–82.PubMedCrossRefGoogle Scholar
  4. 4.
    Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39–51.PubMedCrossRefGoogle Scholar
  5. 5.
    Gennari R, Menard S, Fagnoni F, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res. 2004;10(17):5650–5.PubMedCrossRefGoogle Scholar
  6. 6.
    European Medicines Agency. Herceptin (trastuzumab): summary of product characteristics. 2010. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000278/WC500074922.pdf. Accessed 8 Aug 2013.
  7. 7.
    Genentech Inc. Herceptin (trastuzumab): US prescribing information. 2010. http://www.gene.com/download/pdf/herceptin_prescribing.pdf. Accessed 8 Aug 2013.
  8. 8.
    Gradishar WJ. HER2 therapy: an abundance of riches. N Engl J Med. 2012;366(2):176–8.PubMedCrossRefGoogle Scholar
  9. 9.
    European Medicines Agency. Perjeta (pertuzumab): summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002547/WC500140980.pdf. Accessed 8 Aug 2013.
  10. 10.
    US FDA. Perjeta (pertuzumab): US prescribing information. 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125409lbl.pdf. Accessed 8 Aug 2013.
  11. 11.
    Franklin MC, Carey KD, Vajdos FF, et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004;5(4):317–28.PubMedCrossRefGoogle Scholar
  12. 12.
    Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002;2(2):127–37.PubMedCrossRefGoogle Scholar
  13. 13.
    Scheuer W, Friess T, Burtscher H, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009;69(24):9330–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Adams CW, Allison DE, Flagella K, et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother. 2006;55(6):717–27.PubMedCrossRefGoogle Scholar
  15. 15.
    Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–37.PubMedCrossRefGoogle Scholar
  16. 16.
    Burgess AW, Cho HS, Eigenbrot C, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell. 2003;12(3):541–52.PubMedCrossRefGoogle Scholar
  17. 17.
    Lee-Hoeflich ST, Crocker L, Yao E, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008;68(14):5878–87.PubMedCrossRefGoogle Scholar
  18. 18.
    Bossenmaier B, Hasmann M, Koll H, et al. Presence of HER2/HER3 heterodimers predicts antitumor effects of pertuzumab (Omnitarg) in different human xenograft models [abstract no. 5342]. Proc Am Assoc Cancer Res. 2004;45:1232.Google Scholar
  19. 19.
    Friess T, Bauer S, Burger AM, et al. In vivo activity of recombinant humanized monoclonal antibody 2C4 in xenografts is independent of tumor type and degree of HER2 overexpression [abstract no. 496]. Eur J Cancer. 2002;38(Suppl. 7):S149.Google Scholar
  20. 20.
    Malik MA, Totpal K, Balter I, et al. Dose-response studies of recombinant humanized monoclonal antibody 2C4 in tumor xenograft models [abstract no. 773]. Proc Am Assoc Cancer Res. 2003;44(2nd ed):150.Google Scholar
  21. 21.
    Nahta R, Hung M-C, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004;64(7):2343–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Fuentes G, Scaltriti M, Baselga J, et al. Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism. Breast Cancer Res. 2011;13(3):R54.PubMedCrossRefGoogle Scholar
  23. 23.
    Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010;28(7):1138–44.PubMedCrossRefGoogle Scholar
  24. 24.
    Cortes J, Baselga J, Fumoleau P, et al. Pertuzumab and trastuzumab: exploratory biomarker correlations with clinical benefit in patients with metastatic HER2-positive breast cancer [abstract no. 1066]. J Clin Oncol. 2010;28(15 Suppl. 1).Google Scholar
  25. 25.
    Cortes J, Fumoleau P, Bianchi GV, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30(14):1594–600.PubMedCrossRefGoogle Scholar
  26. 26.
    Garg A, Li J, Clark E, et al. Exposure-response (E-R) analysis of pertuzumab (PTZ) in patients with HER2-positive (HER2+) metastatic breast cancer (MBC): effect on QTc prolongation and other ECG parameters [abstract no. PI-78]. Clin Pharmacol Ther. 2013;93(Suppl. 1):S42.Google Scholar
  27. 27.
    Attard G, Kitzen J, Blagden SP, et al. A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer. 2007;97(10):1338–43.PubMedCrossRefGoogle Scholar
  28. 28.
    Yamamoto N, Yamada Y, Fujiwara Y, et al. Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (pertuzumab, RO4368451) in Japanese patients with solid tumors. Jpn J Clin Oncol. 2009;39(4):260–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005;23(11):2534–43.PubMedCrossRefGoogle Scholar
  30. 30.
    Gianni L, Lladó A, Bianchi G, et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28(7):1131–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Cortes J, Swain S, Kudaba I, et al. Pharmacokinetics (Pk) of pertuzumab (P) with trastuzumab (T) and docetaxel (D) in HER2-positive first-line metastatic breast cancer (MBC): results from the phase III trial CLEOPATRA [abstract no. 344P]. 37th Congress of the European Society for Medical Oncology, 28 Sep-2 Oct 2012, Vienna.Google Scholar
  32. 32.
    Ng CM, Lum BL, Gimenez V, et al. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res. 2006;23(6):1275–84.PubMedCrossRefGoogle Scholar
  33. 33.
    Baselga J, Cortés J, Kim S-B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–19.PubMedCrossRefGoogle Scholar
  34. 34.
    US FDA. Center for Drug Evaluation and Research medical review of pertuzumab. 2012. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125409Orig1s000MedR.pdf. Accessed 8 Aug 2013.
  35. 35.
    Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461–71.PubMedCrossRefGoogle Scholar
  36. 36.
    Cortes J, Baselga J, Im YH, et al. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol. 2013. doi: 10.1093/annonc/mdt274.
  37. 37.
    Swain SM, Ewer MS, Cortés J, et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist. 2013;18:257–64.PubMedCrossRefGoogle Scholar
  38. 38.
    Baselga J, Cortes J, Im S-A, et al. Adverse events with pertuzumab and trastuzumab: evolution during treatment with and without docetaxel in CLEOPATRA [abstract no. 597]. J Clin Oncol. 2012;30(15 Suppl. 1).Google Scholar
  39. 39.
    Cardoso F, Harbeck N, Fallowfield L, et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl. 7):vii11–9.PubMedCrossRefGoogle Scholar
  40. 40.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer (version 2.2013). 2013. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 15 Jul 2013.
  41. 41.
    Miles D, Peretz-Yablonski T, Ciruelos E, et al. Pertuzumab in combination with trastuzumab and a taxane for the first-line treatment of patients with HER2-positive advanced breast cancer: a single arm phase IIIb study (PERUSE) [abstract no. 409TiP]. 37th Congress of the European Society for Medical Oncology, 27 Sep-1 Oct 2012, Vienna.Google Scholar
  42. 42.
  43. 43.
    Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.PubMedCrossRefGoogle Scholar
  44. 44.
    Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013. doi: 10.1093/annonc/mdt182.Google Scholar
  45. 45.
    Ellis PA, Barrios CH, Im Y, et al. MARIANNE: a phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC) [abstract no. TPS102]. J Clin Oncol. 2011;29(15 Suppl. 1).Google Scholar
  46. 46.
    Hoffman-La Roche. A study of trastuzumab emtansine (T-DM1) plus pertuzumab/pertuzumab placebo versus trastuzumab [Herceptin] plus a taxane in patients with metastatic breast cancer (MARIANNE) [ClinicalTrials.gov identifier NCT01120184]. US National Institutes of Health, ClincialTrials.gov [online]. 2013. http://clinicaltrials.gov/ct2/show/NCT01120184?term=NCT01120184&rank=1. Accessed 8 Aug 2013.
  47. 47.
    von Minckwitz G, Baselga J, Bradbury I, et al. Adjuvant Pertuzumab and Herceptin IN IniTial therapY of breast cancer: APHINITY [abstract no. OT1-02-04]. Cancer Res. 2011;71(24 Suppl. 3):602S.Google Scholar
  48. 48.
    Hoffman-La Roche. A study of pertuzumab in addition to chemotherapy and Herceptin (trastuzumab) as adjuvant therapy in patients with HER2-positive primary breast cancer. [ClinicalTrials.gov identifier NCT01358877]. US National Institutes of Health, ClincialTrials.gov [online]. 2013. http://clinicaltrials.gov/ct2/show/NCT01358877?term=NCT01358877&rank=1. Accessed 8 Aug 2013.
  49. 49.
    Hoffman-La Roche. A study of pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, metastatic HER2-positive breast cancer. [ClinicalTrials.gov identifier NCT01491737]. US National Institutes of Health, ClincialTrials.gov [online]. 2013. http://clinicaltrials.gov/ct2/show/NCT01491737?term=NCT01491737&rank=1. Accessed 8 Aug 2013.
  50. 50.
    Hoffman-La Roche. A study of pertuzumab in combination with Herceptin (trastuzumab) and vinorelbine in first line in patients with metastatic or locally advanced HER2-positive breast cancer. 2013. http://clinicaltrials.gov/ct2/show/NCT01565083?term=pertuzumab+AND+breast&rank=16&submit_fld_opt=. Accessed 8 Aug 2013.
  51. 51.
    Andersson M, Lopez-Vega JM, Del Mastro L, et al. Pertuzumab and trastuzumab in combination with vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer (LABC/MBC): a single-arm, two-cohort, phase II study (VELVET) [abstract no. 408TiP]. Ann Oncol. 2012;23(Suppl. 9):ix142.Google Scholar
  52. 52.
    Genentech. An observational study of pregnancy and pregnancy outcomes in women with breast cancer treated with Herceptin or Perjeta in combination with Herceptin during pregnancy or within 6 months prior to conception (MotHER). [ClinicalTrials.gov identifier NCT00833963]. US National Institutes of Health, ClincialTrials.gov [online]. 2012. http://clinicaltrials.gov/ct2/show/NCT00833963?term=NCT00833963&rank=1. Accessed 8 Aug 2013.

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.AdisAucklandNew Zealand

Personalised recommendations